Graves' disease and hyperthyroidism: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 0
• PD-L1 0
• SGLT2 0
• TP53 0
• BRAF 0
• CTLA-4 0
• EGFR 0
• FTO 0
• GLP-1 0
• PCSK9 0
• RAS 0
• TERT 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

1 of 1 running projects, newest first. Listed amounts together: €4.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Organoids 1
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Proteomics 3
• Metabolomics 9
• Mass Spectrometry 5
• Flow Cytometry 3
• Immunohistochemistry 7
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 49
• Machine Learning 15
• Deep Learning 5
• Cohort Studies 69
• Genome-Wide Association Study 25

• Fluoropolymer-Mediated Delivery of a Dual TSHR/IGF1R-Targeting CRISPR-Cas9 System for Localized Therapy in Thyroid-Associated Ophthalmopathy.

  Adv Mater, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.